ClinicalTrials.gg
CompletedNCT04784000Updated Jul 29, 2021

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

A Phase 1 interventional study of Period 1: AT-527 550 mg and Period 2: carbamazepine in Healthy Volunteer Study, sponsored by Atea Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-29.

Sponsored by Atea Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in healthy adult subjects.

02

Conditions studied

  • Healthy Volunteer Study
03

In context

Lead sponsor

Atea Pharmaceuticals, Inc. is the lead sponsor of 33 studies on the registry; 1 is open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 4 (16%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must agree to use two methods of from Screening through 90 days after administration of the last dose of study drug
  • Females must have a negative pregnancy test at Screening and prior to dosing
  • Minimum body weight of 50 kg and (BMI) of 18-29 kg/m2
  • Willing to comply with the study requirements and to provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Infected with virus, virus, or COVID-19
  • Abuse of alcohol or drugs
  • Use of other drugs within 28 days of dosing
  • Use of other prescription drugs with 28 days of dosing
  • Other medical conditions or laboratory abnormalities
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    AT-527 550 mg + carbamezepine

    Drug: Period 1: AT-527 550 mg · Drug: Period 2: carbamazepine · Drug: Period 3: AT-527 550 mg + carbamazepine

  • Experimental
    AT-527 1100 mg + carbamezepine

    Drug: Period 1: AT-527 550 mg · Drug: Period 2: carbamazepine · Drug: Period 3: AT-527 1100 mg + carbamazepine

Interventions

  • AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1

    Also known as: AT-527 is also known as RO7496998

  • DrugPeriod 2: carbamazepine

    Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25

  • DrugPeriod 3: AT-527 550 mg + carbamazepine

    AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26

    Also known as: AT-527 is also known as RO7496998

  • DrugPeriod 3: AT-527 1100 mg + carbamazepine

    AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26

    Also known as: AT-527 is also known as RO7496998

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of AT-527 (RO7496998)

    Maximum plasma concentration (Cmax)

    Time frame: Day 1 vs Day 26

  2. Pharmacokinetics (PK) of AT-527 (RO7496998)

    Area under the concentration-time curve (AUC)

    Time frame: Day 1 vs Day 26

07

Study locations

1 site
  • Atea Study Site
    Montreal, Quebec, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Apr 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 5, 2021
StartActual
Mar 1, 2021
Primary completionActual
Apr 10, 2021
CompletionActual
Apr 10, 2021
Last update
Jul 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04784000
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
Mar 1, 2021
Primary completion
Apr 10, 2021
Completion
Apr 10, 2021
Last update
Jul 29, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AT-511

Start the discussion